

### CLAIM LISTING

1-20. (Canceled)

21. (Currently amended)     An immunologically active chimeric anti-CD20 antibody, wherein the antibody comprises having a variable light chain variable region comprising the amino acid sequence shown in as residues 23 to 128 of SEQ ID NO: 4 and a variable heavy chain variable region comprising the amino acid sequence shown in as residues 20 to 140 of SEQ ID NO: 6.

22-25. (Canceled)

26. (Previously presented)     The chimeric anti-CD20 antibody of Claim 21 which is an IgG1.

27-28. (Canceled)

29. (Currently amended)     The chimeric anti-CD20 antibody of Claim 21 ~~which comprises~~ wherein a radiolabel is attached to the antibody.

30. (Previously presented)     The chimeric anti-CD20 antibody of Claim 29 wherein the radiolabel is selected from the group consisting of yttrium-90, indium-111, and iodine-131.

31. (Currently amended)     The chimeric anti-CD20 antibody of Claim 21 wherein the radiolabel is attached to the antibody ~~via~~ by a chelator.

32. (Previously presented)     The chimeric anti-CD20 antibody of the Claim 31 wherein the chelator is MX-DTPA.

33-40. (Canceled)

41. (Currently amended) A ~~pharmaceutical~~ composition comprising a chimeric anti-CD20 antibody according to Claim 21 and a ~~pharmaceutically acceptable~~ pharmaceutical carrier.

42. (Currently amended) ~~A n imaging~~ A composition comprising a chimeric anti-CD20 antibody according to Claim 21 and ~~an a~~ a pharmaceutically acceptable carrier buffer.

43. (Currently amended) The ~~pharmaceutical~~ composition of Claim 41 or 42 wherein ~~which~~ comprises a radiolabel is attached to the antibody.

44. (Canceled)

45. (Currently amended) The ~~pharmaceutical~~ composition of Claim 43 wherein the radiolabel is yttrium-90 or iodine-131.

46. (Currently amended) The ~~imaging~~ composition of Claim ~~44~~ 43 wherein the radiolabel is indium-111.

47. (Currently amended) The ~~pharmaceutical~~ composition of Claim 41 or 42 which is suitable for parenteral administration.

48. (Currently amended) The ~~pharmaceutical~~ composition of Claim 47 wherein the parenteral administration is selected from the group consisting of ~~subcutaneous~~, intravenous, intramuscular, vaginal, intraperitoneal, and subcutaneous administration.

49-50. (Canceled)

51. (Currently amended) The ~~pharmaceutical~~ composition of Claim 41 or 42 which is formulated to deliver an effective dose ranging from about 0.01 to 30 mg/kg body weight upon administration to a patient.
52. (Currently amended) The ~~pharmaceutical~~ composition of Claim 51 wherein the dose ranges from about 0.01 to about 25 mg/kg body weight.
53. (Currently amended) The ~~pharmaceutical~~ composition of Claim 51 wherein the dose ranges from about 0.4 mg to about 20 mg/kg body weight.
54. (Currently amended) The ~~imaging~~ composition of Claim ~~42~~ 43 which is formulated to deliver a dose of radiation ranging from about 1 to 10 mCi upon administration to a patient.
55. (Currently amended) The ~~imaging~~ composition of Claim 54 wherein the radiolabel is indium-111.
56. (Currently amended) The ~~imaging~~ composition of Claim 55 wherein the dose of radiation is about 5 mCi.
57. (Currently amended) The ~~pharmaceutical~~ composition of Claim 43 which is non-marrow ablative ~~myeloablative~~ when administered to a patient.
58. (Currently amended) An isolated anti-CD20 antibody, wherein the antibody comprising comprises a variable light chain variable region comprising the amino acid sequence shown in as residues 23 to 128 of SEQ ID NO: 4 and a heavy chain variable region comprising the amino acid sequence shown in as residues 20 to 140 of SEQ ID NO: 6.

59. (Previously presented) The anti-CD20 antibody of Claim 58 wherein the antibody is murine.
60. (Currently amended) The anti-CD20 antibody of Claim 58 ~~59~~ further comprising wherein a radiolabel is attached to the antibody.
61. (Previously presented) The anti-CD20 antibody of Claim 60 wherein the radiolabel is selected from the group consisting of yttrium-90, indium-111, and iodine-131.
62. (Previously presented) The anti-CD20 antibody of Claim 61 wherein the radiolabel is yttrium-90.
- 63-67. (Canceled)
68. (New) The anti-CD20 antibody of Claim 58 wherein a chelator is attached to the antibody.
69. (New) A composition comprising an anti-CD20 antibody according to Claim 58 and a pharmaceutical carrier.
70. (New) A composition comprising an anti-CD20 antibody according to Claim 58 and a pharmaceutically acceptable buffer.
71. (New) The chimeric antibody of Claim 21 wherein the antibody is not conjugated to a toxin or radioisotope.
72. (New) The chimeric antibody of Claim 21 wherein the antibody comprises a human light chain kappa constant region and a human heavy chain gamma 1 constant region.